Repare Therapeutics Inc. announced the approval of the acquisition of all of its issued and outstanding common shares by XenoTherapeutics, Inc.
The special resolution approving the arrangement was supported by a high percentage of shareholder votes.
The arrangement is subject to the approval of the Superior Court of Qu\u00e9bec and other closing conditions.
Shareholder Approval
Shareholders voted in favor of the acquisition with a high percentage, indicating confidence in the transaction.
Compensation Approval
Compensation for named executive officers related to the arrangement was also approved by shareholders.
Liquidation Approval
In case of termination, shareholders support the voluntary liquidation and appointment of a liquidator for Repare.
- The approval by shareholders reflects a positive sentiment towards the acquisition and the future direction of Repare Therapeutics Inc.
- The completion of the arrangement, pending court approval, is expected to occur by January 28, 2026, marking a significant milestone for the company.
The acquisition approval by Repare Therapeutics Inc. shareholders signifies a significant step towards the company's growth and future prospects under XenoTherapeutics, Inc. leadership.